Old Web
English
Sign In
Acemap
>
Paper
>
2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)
2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)
2015
Herbert Hurwitz
Yousuf Zafar
Mark Kozloff
Joleen M Hubbard
E. Van Cutsem
Jaafar Bennouna
Dirk Arnold
Tanios S. Bekaii-Saab
Stefanie Srock
C. Revil
S. Fish
V. Barue
A. Grothey
Keywords:
Pathology
Bevacizumab
Colorectal cancer
Observational study
Medicine
Oncology
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]